Skip to main content
OpenTrials
Completed

NCT Number: NCT00449683

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidepressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Thomas Jefferson University, Department of Psychiatry

Philadelphia, Pennsylvania, 19107, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 - 75 years
  • Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR)
  • Presence of excessive sweating by self-report
  • The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption
  • Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative
  • Excessive sweating has persisted for at least 4 weeks prior to baseline assessment
  • The excessive sweating is rated by the patient as at least moderately bothersome.
  • Episodes of excessive sweating occur at least twice a week for last 4 weeks

Exclusion criteria

  • Presence of another known disease that could potentially cause excessive sweating
  • Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past
  • Blood pressure less than 110 mm Hg systolic at the screening or baseline visits
  • Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).
  • Current antihypertensive treatment
  • History of significant cardiac disease, including coronary artery disease
  • Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)
  • History of priapism (persistent and painful erection)

Treatment and study plan

Terazosin

Drug

off-label use of terazosin to treat antidepressant-induced sweating

Other names: Hytrin

Primary outcomes

  1. To study whether terazosin 1 to 4 mg/ day is effective in reducing antidepressant-induced sweating

    Time frame: 8 weeks

  2. To test a novel device for ambulatory monitoring of sweating which is required to study this phenomenon since ADIES is usually episodic

    Time frame: 8 weeks

Secondary outcomes

  1. To determine if the severity of sweating at baseline is correlated with baseline urinary norepinephrine levels

    Time frame: 8 weeks

  2. To determine if response to treatment correlated with baseline urinary norepinephrine levels and with changes in these levels during the study.

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Thomas Jefferson University

Other

Collaborators

  • National Alliance for Research on Schizophrenia and Depression

Registry information

Official study title

Antidepressant Induced Excessive Sweating: Measurement and Treatment With Terazosin

Acronym: ADIES

Important dates

Study start
2007
Primary completion
2013
Study completion
2013
First posted
Mar 20, 2007
Registry last updated
Aug 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.